Perampanel
Grade II Glioma
Mayo ClinicSmall moleculePhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Grade II Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pamiparib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | B |
FET Thomas Hope | Phase 2 | B |
Ivosidenib National Cancer Institute (NCI) | Phase 2 | CCC |
Olaparib National Cancer Institute (NCI) | Phase 2 | CCC |
Selpercatinib National Cancer Institute (NCI) | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
Perampanel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →